This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Connor, T. P. Articles by Philipp, M. T. Search for Related Content PubMed PubMed Citation Articles by O'Connor, T. P. Articles by Philipp, M. T.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, May 2004, p. 458-462, Vol. 11, No. 3
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.3.458-462.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Dogs Vaccinated with Common Lyme Disease Vaccines Do Not Respond to IR₆, the Conserved Immunodominant Region of the VlsE Surface Protein of Borrelia burgdorferi

Department of Research and Development, IDEXX Laboratories, Inc., Westbrook, Maine 04092,¹ Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, Louisiana 70433²

Received 16 September 2003/ Returned for modification 14 November 2003/ Accepted 16 February 2004

A 25-amino-acid synthetic peptide (C₆ peptide) derived from an immunodominant conserved region (designated IR₆) of the VlsE protein of Borrelia burgdorferi has been identified and used to construct immunoenzyme-based diagnostic procedures. These procedures have excellent sensitivity and specificity. Previous reports have demonstrated the usefulness of the C₆ peptide as an antigen for the serodiagnosis of human and canine Lyme disease. Results indicated that assays based on the C₆ peptide were nonreactive to sera from vaccinated nonexposed animals. The purpose of the present study was to confirm these results in a controlled trial by testing sera from experimentally vaccinated dogs known to be uninfected. Nine specific-pathogen-free beagles were assigned to one of three vaccine groups, each containing three dogs. Each group received one of three commercial Lyme vaccines: RECOMBITEK Lyme (Merial), LymeVax (Fort Dodge Animal Health), and Galaxy Lyme (Schering-Plough Animal Health). Each animal was administered a total of five doses of vaccine over a period of 39 weeks. Serum samples were collected prior to vaccination and then on a weekly basis from weeks 3 to 18 and from weeks 33 to 43. Selected samples were tested by the immunofluorescence assay (IFA) and the Western blot (WB) assay using whole-cell B. burgdorferi antigen extracts, and the results were compared to those obtained with two immunoenzyme-based procedures formatted by using the C₆ peptide. Serum specimens from all animals were reactive to the IFA and WB assay at week 5 and became highly reactive following the administration of multiple doses of vaccine. All serum specimens were uniformly nonreactive in the C₆ peptide immunoenzyme procedures at all time points throughout the study.

This article has been cited by other articles:

• Philipp, M. T., Wormser, G. P., Marques, A. R., Bittker, S., Martin, D. S., Nowakowski, J., Dally, L. G. (2005). A Decline in C6 Antibody Titer Occurs in Successfully Treated Patients with Culture-Confirmed Early Localized or Early Disseminated Lyme Borreliosis. CVI 12: 1069-1074 [Abstract] [Full Text]